
Twist Bioscience Corporation
NASDAQ•TWST
CEO: Dr. Emily Marine Leproust Ph.D.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 2018-10-31
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Contact Information
681 Gateway Boulevard, South San Francisco, CA, 94080, United States
800-719-0671
Market Cap
$2.54B
P/E (TTM)
-32.2
26.9
Dividend Yield
--
52W High
$55.33
52W Low
$23.30
52W Range
Rank59Top 87.6%
2.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$99.01M+16.88%
4-Quarter Trend
EPS
-$0.45-25.00%
4-Quarter Trend
FCF
-$24.24M+39.94%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Grows 20% Total revenues reached $376.6 M, marking a 20% increase driven by NGS tools and synthetic genes growth.
Gross Margin Significantly Improves Gross margin increased 8.1 points to 50.7% due to revenue growth and continuous process improvement cost savings.
Operational Loss Narrows Loss from operations improved substantially to $(136.3) M, reflecting higher gross profit and no asset impairment charges.
DNA Synthesis Volume Rises Number of genes shipped increased 22% to 938 thousand units, indicating strong operational efficiency and market demand.
Risk Factors
Profitability Remains Uncertain Company incurred net losses since inception; profitability achievement is not certain, posing ongoing investment risk.
Dependence on Core Technology Continued success relies heavily on disruptive silicon chip DNA synthesis technology and maintaining leading market position.
Single-Source Supplier Risk Dependent on one single-source supplier for a critical component; failure could cause delays in DNA synthesis capacity.
Cybersecurity and IT Risks Risk of system disruption or data breaches from cyberattacks or insider threats could adversely affect operations and reputation.
Outlook
Expand Global Presence Strategy includes maintaining synthetic DNA leadership while expanding global presence and entering new international markets effectively.
Leverage Manufacturing Investment Plans to leverage investment in the Wilsonville, Oregon manufacturing facility to support future product portfolio expansion.
Advance Biopharma Offerings Focus on expanding antibody and protein production capabilities alongside characterization assays to support drug discovery projects.
Integrate AI Technologies Intent to integrate artificial intelligence and machine learning to improve operational efficiency and enhance product development solutions.
Peer Comparison
Revenue (TTM)
QDEL$2.72B
$1.50B
ATRC$518.31M
Gross Margin (Latest Quarter)
94.2%
QDEL93.2%
OCUL87.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| LQDA | $3.30B | -26.9 | -296.8% | 72.2% |
| VERA | $3.26B | -11.8 | -50.9% | 14.9% |
| TWST | $2.54B | -32.2 | -16.8% | 11.8% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.7%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Next earnings:Feb 2, 2026
EPS:-$0.49
|Revenue:$100.30M
Reports
All Years
Form 10-K - FY 2025
Period End: Sep 30, 2025|Filed: Nov 17, 2025|Revenue: $376.57M+20.3%|EPS: $-1.30+63.9%MissForm 10-Q - Q3 2025
Period End: Jun 30, 2025|Filed: Aug 4, 2025|Revenue: $96.06M+17.9%|EPS: $0.34-123.1%BeatForm 10-Q - Q2 2025
Period End: Mar 31, 2025|Filed: May 5, 2025|Revenue: $92.79M+23.2%|EPS: $-0.66-16.5%MissForm 10-Q - Q1 2025
Period End: Dec 31, 2024|Filed: Feb 3, 2025|Revenue: $88.71M+24.1%|EPS: $-0.53-29.3%BeatForm 10-K - FY 2024
Period End: Sep 30, 2024|Filed: Nov 18, 2024|Revenue: $312.97M+27.7%|EPS: $-3.60+0.0%MissForm 10-Q - Q3 2024
Period End: Jun 30, 2024|Filed: Aug 2, 2024|Revenue: $81.46M+27.8%|EPS: $-1.47+45.5%MissForm 10-Q - Q2 2024
Period End: Mar 31, 2024|Filed: May 2, 2024|Revenue: $75.30M+25.1%|EPS: $-0.79-24.0%BeatForm 10-Q - Q1 2024
Period End: Dec 31, 2023|Filed: Feb 2, 2024|Revenue: $71.50M+31.8%|EPS: $-0.75+1.4%Beat